EvolveImmune Therapeutics has filed a notice of an exempt offering of securities to raise $26,000,000.00 in New Debt Financing.
According to filings with the U.S. Securities and Exchange Commission, EvolveImmune Therapeutics is raising $26,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Stephen Bloch played a key role in…